Medscape Cost in 2026: What It Charges, and What the Paid References Buy

The short answer: Medscape costs nothing. Apple's US App Store listing shows it as free with no in-app purchases at all, which is unusual in this category and worth stating plainly: there is no premium tier, no paywalled feature and no upgrade waiting for you three months in. Registration gets you a drug reference covering more than 9,200 drugs, a multi-drug interaction checker, a pill identifier, more than 450 medical calculators, clinical news across 30-plus specialties, and free CME and CE that carries ABIM MOC points. WebMD Health Corporation funds it through advertising.

That answer is short enough that the more useful question is the one underneath it: if Medscape gives all that away, what exactly are clinicians paying for elsewhere? Because the same phone often carries a $179.99-a-year Epocrates subscription, a $29.99-a-month Lexidrug subscription, or an institutional UpToDate license that costs an order of magnitude more. Understanding what those buy, and what they do not, is the actual buying decision.

Does Medscape cost money?

No. Not now, and not through a tier you get upgraded into later. The App Store listing is explicit that the app is free and lists no in-app purchases, which is a stronger signal than a marketing page saying "free to get started." Plenty of clinical apps say that and then meter the useful parts. Medscape does not.

What you register for is a real account rather than a trial. Medscape verifies clinical status for some features and personalizes content by specialty, and the registration is how it targets both the editorial and the advertising. There is no credit card step and no expiry.

The honest caveat is the funding model rather than a hidden fee. Sponsored content and pharmaceutical advertising share space with reference material, and the news feed carries promoted items. Some clinicians find that genuinely distracting next to prescribing information; others have used it for fifteen years and stopped noticing. It is a preference, not a defect, and it is the only cost the product actually imposes on you.

What do you get for free?

More than most people expect, which is the point worth making. The pieces a prescriber uses day to day:

• Drug reference. Prescribing information on more than 9,200 drugs, including dosing, adverse effects, contraindications and monitoring, in a monograph format.
• Drug interaction checker. A multi-drug checker you can run against a full medication list.
• Pill identifier. Identification by imprint, shape and color.
• Medical calculators. More than 450, organized by specialty, covering the risk scores and dosing calculations clinicians reach for repeatedly.
• Clinical news. FDA approvals, conference coverage and trial data across more than 30 specialties.
• CME and CE. Free credits, including ABIM MOC points, which map onto real recertification requirements rather than being a token perk.
• AI features. An AI search for clinical questions, plus Scribe for visit transcription.

The calculators and the free CME are the parts that quietly justify keeping it installed even if you prefer another app for drug lookups. Paying separately for a calculator app or for CME credits, when a free tool carries both, is a small recurring waste that adds up across a practice.

How does Medscape compare to Epocrates on price?

Epocrates also has a free tier, so the comparison is not free versus paid. It is free versus free-plus-an-upsell. Epocrates gives away more than 6,000 drug monographs, a pill identifier and an interaction checker, then charges $179.99 a year or $24.99 a month for epocrates+, verified at the US App Store listing in August 2026.

Two details matter when you weigh that. First, the Epocrates free interaction checker is capped at 30 medications per check. For most encounters that ceiling is irrelevant; for a long-term care resident on a genuinely long list, it is exactly the patient in whom you most wanted the check. Second, and more importantly, epocrates+ does not buy you better drug data. It adds the disease reference, differential diagnosis support, lab value interpretation and dosing calculators. The drug content you already had.

So on drug reference alone, Medscape covers more drugs than the free Epocrates tier and costs the same, which is nothing. Epocrates earns its following on interface speed rather than coverage, and that is a legitimate reason to prefer it. We lay the two out feature by feature in our Epocrates versus Medscape comparison, and the paid tier gets its own breakdown in what Epocrates actually costs.

How does it compare to the paid references?

Differently enough that the price gap makes sense, which is worth saying because "Medscape is free, why pay" is an incomplete argument.

UpToDate sells graded editorial recommendations written by named physician authors. When you need a position you can cite and defend in a chart note or a morbidity and mortality conference, that grading is the product. Wolters Kluwer does not publish an individual price publicly; the store requires you to select a country and professional role before it quotes anything, so treat any confident annual figure you find on a software directory site with suspicion.

Lexidrug, which most clinicians still call Lexicomp, sells drug-monograph depth: IV compatibility, formulation detail, administration specifics and the granularity pharmacists work from. Its personal mobile subscription lists at $29.99 a month, roughly $360 a year, with no free tier. Institutional pricing is negotiated and never published. Micromedex is the same story with even less visibility. We cover both in what Lexicomp costs and what Micromedex costs.

The pattern across all of them: the free tools are excellent at breadth and lookup speed, and the paid tools are bought for depth or for defensibility. If neither depth nor defensibility is your bottleneck, you are not missing anything by staying free.

Should a practice pay for a clinical reference at all?

Start by auditing what you already have, because the most common waste in this category is not overpaying. It is paying twice. A striking share of US clinicians hold personal subscriptions to references their hospital, group or medical library already licenses, usually because the institutional access is signposted badly and the personal subscription was easier to set up.

Three things to check before any renewal. Whether your EHR already surfaces an embedded drug reference inside the chart, because Lexidrug in particular is licensed into Epic, MEDITECH and Cerner and appears as a context link many clinicians never notice. Whether your medical library or alumni association carries a license, since borrowing rights often include it. And whether a specialty society membership you already pay for bundles access, which several do.

For a group practice, the fragmentation itself is the problem worth fixing. Individual clinicians expense individual subscriptions, nobody holds a list, and the same product gets bought four times at retail instead of once at a group rate. Practices that get this under control usually do it by routing every recurring vendor charge through a single approval and payment workflow for recurring invoices rather than reimbursing them one card statement at a time. Once the list exists, the duplicates are obvious in an afternoon, and the negotiation with the vendor gets a lot easier when you can say how many seats you actually need.

Where the free tools stop

Medscape, Epocrates and every reference on this list share one structural limit, and it has nothing to do with price. They all wait to be asked.

To catch a problem with the prescription in front of you, you have to remember to run the interaction check, then remember to look up the contraindication, then think about whether the renal function changes the dose, then consider whether a safer agent exists for this patient. That is four separate questions requiring four separate lookups, in a clinic that is already running late. The checks that get missed are almost never checks a clinician decided to skip. They are the ones nobody thought to run.

That gap is what Prescriber.io is built to close. Enter the drug or the scenario once, and interactions, contraindications, allergy blockers, renal and hepatic dose adjustments and guideline-based alternatives come back together in a single card with sources cited on each flag. It is decision support for licensed clinicians, not autonomous prescribing: you review every flag, verify it against official sources, and sign. It sits alongside a reference app rather than replacing one, because looking a drug up and checking a decision are genuinely different jobs.

The bottom line

Medscape is free, and unusually for a free clinical tool, it is free without an asterisk. If your requirement is drug lookups, interaction checking, calculators and CME, you can meet all of it at no cost, and you should confirm that before renewing anything. Pay for a clinical reference when you need something the free tools genuinely do not provide: graded recommendations you can defend, pharmacist-grade monograph depth, or a check that runs automatically at the moment you prescribe rather than only when you remember to ask.